Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 2 3Phase 3 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Neoplasms 1Meningioma 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Arginine × Clear all
NCT07150806 2026-05-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNS

Meningioma

NCT02844387 2016-07-28

Supplementation of L-arginine in Patients With Non-resectable Brain Metastases

Instituto de Oncología Ángel H. Roffo

Phase 1/2 Completed
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡